HGS shares dip on FDA delay

Shares of Human Genome Sciences took a small hit Friday evening after the biotech company said that the FDA was extending its review time for the closely-watched lupus drug benlysta. While the drug was endorsed recently by an FDA panel, it's no great surprise that the agency needed more time to review the therapy as well as the panel vote. The target date for an agency decision is now March 10. Story

Suggested Articles

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.

The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.

Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion in 2018 for up to $1.2 billion.